GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tovecimig   Click here for help

GtoPdb Ligand ID: 14507

Synonyms: ABL001 | CTX-009 | CTX009
Compound class: Antibody
Comment: Tovecimig (CTX-009; formerly ABL001) is a bispecific monoclonal antibody that simultaneously blocks the signalling pathways that are activated by the delta-like ligand-4 (DLL4; Notch signaling) and vascular endothelial growth factor A (VEGF-A) [4]. The VEGF-A binding heavy chains of tovecimig are derived from the established anti-VEGF-A biologic bevacizumab. Two single chain variable fragments (scFv) that bind to human DLL4 are linked to the C-termini of the anti-VEGF-A heavy chains [1].
No information available.
Summary of Clinical Use Click here for help
Tovecimig (CTX-009) was progressed as a clinical candidate for the treatment of advanced/metastatic solid tumours. The FDA granted orphan drug designation in Aprl 2026, for the treatment of biliary tract cancer [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06548412 CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers Phase 1/Phase 2 Interventional M.D. Anderson Cancer Center
NCT07392957 Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma Phase 1/Phase 2 Interventional Washington University School of Medicine
NCT05506943 A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) Phase 2/Phase 3 Interventional Compass Therapeutics The COMPANION-002 study 1
NCT05513742 A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Phase 2 Interventional Compass Therapeutics The COMPANION-003 study 2